The Louisiana State University Health Sciences Center-Shreveport last week finalized a licensing agreement with Massachusetts drug developer Aphios, allowing the company to develop the compound bryostatin-1 as a possible localized treatment for organ transplant rejection.

The deal is a result of a nearly three-year research partnership between Aphios and LSUHSC-S, and is the latest product of a concerted effort at LSUHSC-S to ramp up collaboration between its faculty and industry, a school official told BTW this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.